Drug or treatment

Zolbetuximab clinical trials

• 6Clinical trials
• 1New in 30 days
• 22Countries

Newest trials

All recruiting trials (6)

• Zolbetuximab added to FLOT and durvalumab before surgery for CLDN18.2-positive gastric/GEJ cancer

  This study tests whether adding zolbetuximab to FLOT chemotherapy plus durvalumab can improve tumor response before surgery in adults with CLDN18.2-positive gastric or GEJ cancer.

  Recruiting Phase 2 National Cancer Center, Japan · Saitama and 3 other locations · NCT07872722

• Zolbetuximab with chemotherapy for HER2-negative, Claudin 18.2–positive metastatic gastric or gastroesophageal junction adenocarcinoma

  This project will try zolbetuximab together with FOLFOX or XELOX as first-line treatment for adults whose HER2-negative stomach or gastroesophageal junction cancers strongly express Claudin 18.2.

  Recruiting European Institute of Oncology · Milan · NCT07427992

• Zolbetuximab with paclitaxel and ramucirumab for CLDN18.2-positive stomach and gastro‑esophageal junction cancer

  This treatment tests whether adding zolbetuximab to paclitaxel and ramucirumab helps adults with metastatic gastro‑esophageal adenocarcinoma whose tumors are CLDN18.2‑positive live longer.

  Recruiting Phase 2 Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT06962137

• Zolbetuximab plus pembrolizumab and chemotherapy for stomach and gastroesophageal junction cancer

  This trial will test whether adding zolbetuximab to pembrolizumab and standard chemotherapy helps adults with Claudin 18.2-positive, HER2-negative locally advanced or metastatic stomach or gastroesophageal junction cancer.

  Recruiting at 187 sites Phase 3 Astellas Pharma Inc · Birmingham, Alabama and 252 other locations · NCT06901531

• Evaluating Zolbetuximab in Advanced Gastric Cancer

  This study is testing if a new drug called Zolbetuximab can help people with advanced gastric cancer who have a certain type of tumor, by looking at how well it works and what side effects it might cause.

  Recruiting Yonsei University · Seoul · NCT06767449

• Neoadjuvant zolbetuximab with docetaxel, oxaliplatin and S-1 for locally advanced stomach cancer

  This study will test whether adding zolbetuximab to docetaxel, oxaliplatin, and S-1 before surgery helps people with locally advanced, CLDN18.2-positive stomach cancer shrink tumors and have better outcomes.

  Recruiting at 2 sites Phase 1/2 Asan Medical Center · Seoul and 1 other locations · NCT06732856

Quick answers

How many clinical trials of Zolbetuximab are recruiting right now?

6, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 22 countries. The most sites are in South Korea (3 trials), Belgium (2 trials), Italy (2 trials), Japan (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2, Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →